Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Cancer treatment according to BRCA1 and BRCA2 mutations.

Maxwell KN, Domchek SM.

Nat Rev Clin Oncol. 2012 Sep;9(9):520-8. doi: 10.1038/nrclinonc.2012.123. Epub 2012 Jul 24. Review.

PMID:
22825375
2.

The biological effects and clinical implications of BRCA mutations: where do we go from here?

Stoppa-Lyonnet D.

Eur J Hum Genet. 2016 Sep;24 Suppl 1:S3-9. doi: 10.1038/ejhg.2016.93. Review.

3.

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S.

Nat Med. 2017 Apr;23(4):517-525. doi: 10.1038/nm.4292. Epub 2017 Mar 13.

PMID:
28288110
4.

BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.

Pothuri B.

Ann Oncol. 2013 Nov;24 Suppl 8:viii22-viii27. doi: 10.1093/annonc/mdt307. Review.

PMID:
24131965
5.

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.

Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B.

Int J Oncol. 2015 Jul;47(1):262-8. doi: 10.3892/ijo.2015.3003. Epub 2015 May 12.

PMID:
25975349
6.

Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families.

Kang HC, Kim IJ, Park JH, Kwon HJ, Won YJ, Heo SC, Lee SY, Kim KH, Shin Y, Noh DY, Yang DH, Choe KJ, Lee BH, King SB, Park JG.

Hum Mutat. 2002 Sep;20(3):235.

PMID:
12204006
7.

Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.

Ibrahim SS, Hafez EE, Hashishe MM.

J Exp Clin Cancer Res. 2010 Jun 25;29:82. doi: 10.1186/1756-9966-29-82.

8.

BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.

Cherbal F, Salhi N, Bakour R, Adane S, Boualga K, Maillet P.

Dis Markers. 2012;32(6):343-53. doi: 10.3233/DMA-2012-0893.

9.

Advances in PARP inhibitors for the treatment of breast cancer.

Dizdar O, Arslan C, Altundag K.

Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20. Review.

PMID:
26485111
10.

The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.

De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, Thomas CJ, Deng CX.

Int J Biol Sci. 2006;2(4):179-85. Epub 2006 Jun 10.

11.

Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.

Wang W, Figg WD.

Cancer Biol Ther. 2008 Jul;7(7):1004-5. Review.

12.

BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.

Cherbal F, Bakour R, Adane S, Boualga K, Benais-Pont G, Maillet P.

Dis Markers. 2010;28(6):377-84. doi: 10.3233/DMA-2010-0718.

13.

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.

Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, Ariffin H, Thong MK, Chin KF, Mohd Taib NA, Yip CH, Teo SH.

Breast Cancer Res. 2012 Apr 16;14(2):R66.

14.

Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.

Giannini G, Capalbo C, Ristori E, Ricevuto E, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A.

Breast Cancer Res Treat. 2006 Nov;100(1):83-91. Epub 2006 May 9.

PMID:
16847550
15.

Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.

Walsh CS.

Gynecol Oncol. 2015 May;137(2):343-50. doi: 10.1016/j.ygyno.2015.02.017. Epub 2015 Feb 25. Review.

16.

Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba.

Rodriguez RC, Esperon AA, Ropero R, Rubio MC, Rodriguez R, Ortiz RM, Anta JJ, de los Rios M, Carnesolta D, del Olivera MC, Vansam SS, Royer R, Akbari MR, Donenberg T, Narod SA.

Fam Cancer. 2008;7(3):275-9. doi: 10.1007/s10689-008-9187-7. Epub 2008 Feb 20.

PMID:
18286383
17.

Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.

Zhang J, Pei R, Pang Z, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.

Breast Cancer Res Treat. 2012 Apr;132(2):421-8. doi: 10.1007/s10549-011-1596-x. Epub 2011 May 26.

PMID:
21614564
18.

Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer.

Ramus SJ, Harrington PA, Pye C, DiCioccio RA, Cox MJ, Garlinghouse-Jones K, Oakley-Girvan I, Jacobs IJ, Hardy RM, Whittemore AS, Ponder BA, Piver MS, Pharoah PD, Gayther SA.

Hum Mutat. 2007 Dec;28(12):1207-15.

PMID:
17688236
19.

Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.

Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, Timms K, Garber JE, Herold C, Ellisen L, Krejdovsky J, DeLeonardis K, Sedgwick K, Soltis K, Roa B, Wenstrup RJ, Hartman AR.

Cancer. 2015 Jan 1;121(1):25-33. doi: 10.1002/cncr.29010. Epub 2014 Sep 3.

20.

Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.

De Picciotto N, Cacheux W, Roth A, Chappuis PO, Labidi-Galy SI.

Crit Rev Oncol Hematol. 2016 May;101:50-9. doi: 10.1016/j.critrevonc.2016.02.014. Epub 2016 Feb 27. Review.

PMID:
26964893

Supplemental Content

Support Center